TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06833073: A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 308 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT06833073 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06833073 Rescue Dossier →